Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben in the Treatment of Gastroparesis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Randomised Clinical Trial: Safety, Pharmacokinetics and Pharmacodynamics of Trazpiroben (TAK-906), a Dopamine D2 /D3 Receptor Antagonist, in Patients With Gastroparesis
Aliment. Pharmacol. Ther. 2021 Jun 20;[EPub Ahead of Print], B Kuo, C Scimia, G Dukes, W Zhang, S Gupta, C Chen, E Chuang, M CamilleriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.